Novo Holdings

← Back to your selection

All recorded activity

Rounds participated in: 3
Confirmed lead rounds: —
New companies: 3
Funding in participating rounds: $313M

By stage

Series C+2

Series B1

By primary sector

Biotech3

By country

United States2

Denmark1

Rounds

3 in all activity

Jul 22

Crystalys Therapeutics

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries B

Role not disclosed

Apr 15

Terremoto Biosciences

Develops highly targeted, small molecule medicines for cancer and rare diseases

$108MSeries C

Role not disclosed

Apr 14

Adcendo

Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment

$75MSeries C

Role not disclosed

← Back to your selection

All recorded activity

Rounds participated in: 3
Confirmed lead rounds: —
New companies: 3
Funding in participating rounds: $313M

By stage

Series C+2

Series B1

By primary sector

Biotech3

By country

United States2

Denmark1

Rounds

3 in all activity

Jul 22

Crystalys Therapeutics

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries B

Role not disclosed

Apr 15

Terremoto Biosciences

Develops highly targeted, small molecule medicines for cancer and rare diseases

$108MSeries C

Role not disclosed

Apr 14

Adcendo

Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment

$75MSeries C

Role not disclosed